Research on the genome of the virus that causes severe acute respiratory syndrome (SARS) has revealed an unusual molecular structure that looks like a promising target for antiviral drugs. A team of ...
EDP-323, an investigational inhibitor of Respiratory Syncytial Virus (RSV), is showing promising results in Phase 2a trials. While other RSV therapies and vaccines are approved for prevention, EDP-323 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results